Hepion Pharmaceuticals Research and Development Expense (Quarterly) Analysis | YCharts

Hepion Pharmaceuticals Inc (HEPA)

1.32 +0.08 (+6.45%) USD | NASDAQ | May 17, 16:00

1.32 0.00 (0.00%) After-Hours: 20:00

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.

Date	Value
December 31, 2023	5.443M
September 30, 2023	8.518M
June 30, 2023	11.88M
March 31, 2023	9.798M
December 31, 2022	7.516M
September 30, 2022	5.740M
June 30, 2022	15.70M
March 31, 2022	4.311M
December 31, 2021	6.910M
September 30, 2021	5.800M
June 30, 2021	4.186M
March 31, 2021	3.499M
December 31, 2020	2.627M
September 30, 2020	3.782M
June 30, 2020	2.950M
March 31, 2020	2.637M
December 31, 2019	1.064M
September 30, 2019	0.8465M
June 30, 2019	0.7557M
March 31, 2019	0.518M
December 31, 2018	1.042M

Date	Value
September 30, 2018	2.168M
June 30, 2018	2.123M
March 31, 2018	2.261M
September 30, 2017	3.964M
June 30, 2017	3.26M
March 31, 2017	2.945M
December 31, 2016	4.318M
September 30, 2016	3.130M
June 30, 2016	4.025M
March 31, 2016	3.187M
December 31, 2015	4.042M
September 30, 2015	3.766M
June 30, 2015	3.590M
March 31, 2015	2.606M
December 31, 2014	1.824M
September 30, 2014	0.3841M
June 30, 2014	0.2189M
March 31, 2014	0.0725M
December 31, 2013	0.0092M
September 30, 2013	0.0136M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

0.7557M

Minimum

Jun 2019

15.70M

Maximum

Jun 2022

5.472M

Average

4.311M

Median

Mar 2022

Research and Development Expense (Quarterly) Benchmarks

Ionis Pharmaceuticals Inc	214.22M
Madrigal Pharmaceuticals Inc	71.24M
Galectin Therapeutics Inc	8.054M
Viking Therapeutics Inc	24.10M
89bio Inc	47.43M